Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Breast Cancer | Research

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Authors: Hai-long Chen, Feng-bo Huang, Qiang Chen, Yong-chuan Deng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly regarding chemotherapy benefit. We evaluated the pathologic response to neoadjuvant chemotherapy (NAC) in ER low positive tumors (ER staining 1-10%) and compared it with ER > 10% positive tumors (ER staining > 10%) and ER-negative tumors. We further explored the differences in recurrence and survival with respect to the ER expression level.

Method

Patients with stages II and III HER2-negative primary breast cancer who received neoadjuvant chemotherapy followed by definitive surgery were categorized according to their ER percentages into three groups: ER-negative, ER low positive, and ER > 10% positive. Logistic regression models were used to assess the association between each variable and pathologic complete response (pCR). Kaplan‒Meier analysis was used to estimate survival outcomes. Cox models were used to adjust for patient and tumor characteristics.

Results

A total of 241 patients were analyzed. Of all patients included, 22 (9.1%) had ER low positive tumors, 159 (66.0%) had ER > 10% positive tumors, and 60 (24.9%) were ER-negative. Low ER positivity was significantly associated with a higher pCR rate than ER > 10% positivity (OR, 0.249; 95% CI, 0.067–0.923; P = 0.038). After a median follow-up time of 32 months, the disease-free survival (DFS) and overall survival (OS) of the patients with ER low positive tumors were significantly worse than those of the patients with ER > 10% positive tumors but similar to those with ER-negative tumors. After adjustment for covariates, ER low positive tumors were significantly associated with worse DFS than ER > 10% positive tumors.

Conclusion

Our results indicated that ER low positive breast cancer presents a better response to neoadjuvant chemotherapy and significantly worse prognosis for patients than those with ER > 10% positive tumors, but similar to the ER-negative group. These data support that this category of patients behaves clinically like patients with ER-negative breast cancer and should be treated differently from patients with ER > 10% positive tumors. Further prospective study is needed.
Appendix
Available only for authorised users
Literature
1.
Dunnwald LK, Rossing MA. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.CrossRefPubMedPubMedCentral
2.
Bardou VJ, Arpino G, Elledge RM, Osborne CK. .Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21:1973–9.CrossRefPubMed
3.
Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S. .Osborne C.K. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000;89:111–7.CrossRefPubMed
4.
Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurkula M, Langman G, Mazzucchelli L, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571–81.CrossRefPubMed
5.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol. 2007;25:3846–52.CrossRefPubMed
6.
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, tamoxifen, alone or in combination trial. J Clin Oncol. 2008;26:1059–65.CrossRefPubMed
7.
Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors–international breast Cancer Study Group. J Clin Oncol. 2008;26:1404–10.CrossRefPubMed
8.
Layfield LJ, Gupta DMooneyEE. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques, and quantitation methods. Breast J. 2000;6:189–96.CrossRefPubMed
9.
Putti TC, Pinder SE, Elston CW, Lee AH. .Ellis I.O. breast pathology practice: most common problems in a consultation service. Histopathology. 2005;47:445–57.CrossRefPubMed
10.
Dowsett M, Cuzick J, Wale C, Howell T, Houghton JBaumM. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23:7512–7.CrossRefPubMed
11.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedPubMedCentral
12.
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Buzdar AU, Symmans WF, Crow JR, et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol. 2014;25:1004–11.CrossRefPubMedPubMedCentral
13.
Early Breast Cancer Trialists’, Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.CrossRef
14.
Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A, Viale G, Veronesi P, Intra M, Luini A, et al. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Clin Breast Cancer. 2014;14:258–64.CrossRefPubMed
15.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020;38:1346–66.CrossRefPubMed
16.
Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ, Ueno NT, Zhang J, Shi W, Qi Y, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1–10% ER-positive by immunohistochemistry. J Clin Oncol. 2012;30:729–34.CrossRefPubMed
17.
Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama C, Dendukuri N, Manjunath S, Correa M, Raman N, et al. A majority of low (1–10%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer. 2014;5:156–65.CrossRefPubMedPubMedCentral
18.
Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012;118:1498–506.CrossRefPubMed
19.
Park YH, Karantza V, Calhoun SR, Park S, Lee S, Kim JY, Yu JH, Kim SW, Lee JE, Nam SJ, et al. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1–10%) breast cancer: a single institution’s experience in Korea. Breast Cancer Res Treat. 2021;189:653–63.CrossRefPubMed
20.
Morgan DA, Refalo NA. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast. 2011;20:215–9.CrossRefPubMed
21.
Van den Eynden GG, Colpaert CG, Vermeulen PB, Weyler JJ, Goovaerts G, van Dam P, Van Marck EA. .Dirix L.Y. comparative analysis of the biochemical and immunohistochemical determination of hormone receptors in invasive breast carcinoma influence of the tumor-stroma ratio. Pathol Res Pract. 2002;198:517–24.CrossRefPubMed
22.
Honma N, Horii R, Iwase T, Saji S, Younes M, Ito Y. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy. Breast. 2014;23:754–62.CrossRefPubMed
23.
Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, et al. Low estrogen receptor (ER)-Positive breast Cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-Positive or ER-Negative disease? Am J Clin Pathol. 2018;150:34–42.CrossRefPubMed
24.
Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK, Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol. 2006;24:5637–44.CrossRefPubMed
25.
Phillips T, Murray G, Wakamiya K, Askaa J, Huang D, Welcher R, Pii K. Allred D.C. Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy. Appl Immunohistochem Mol Morphol. 2007;15:325–31.CrossRefPubMed
26.
Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015;20:474–82.CrossRefPubMedPubMedCentral
27.
Gloyeske NC, Dabbs DJ. Low ER + breast cancer: is this a distinct group? Am J Clin Pathol. 2014;141:697–701.CrossRefPubMed
28.
Yang L, Zhong X, Pu T, Qiu Y, Ye F. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy. World J Surg Oncol. 2018;16:51.CrossRefPubMedPubMedCentral
29.
He Y, Zhang J, Chen H, Zhou Y, Hong L, Ma Y, Chen N. Zhao W.Tong Z. Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients. Front Surg. 2022;9:1037215.CrossRefPubMed
30.
Al-Saleh K, Salah T, Arafah M, Husain S, Al-Rikabi AAbd, El-Aziz N. Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: results from a tertiary Cancer Center in Saudi Arabia. PLoS ONE. 2021;16:e0247802.CrossRefPubMedPubMedCentral
31.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.CrossRefPubMed
32.
Ohara AM, Naoi Y, Shimazu K, Kagara N, Shimoda M, Tanei T, Miyake T, Kim SJ. .Noguchi S. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. Breast Cancer Res Treat. 2019;173:533–43.CrossRefPubMed
33.
Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017;28:2420–8.CrossRefPubMedPubMedCentral
34.
Bouchard-Fortier A, Provencher L, Blanchette CDiorioC. Prognostic and predictive value of low estrogen receptor expression in breast cancer. Curr Oncol. 2017;24:e106–e14.CrossRefPubMedPubMedCentral
35.
Chen T, Zhang N, Moran MS, Su P, Haffty BG. Borderline ER-Positive primary breast Cancer gains no significant Survival Benefit from Endocrine Therapy: a systematic review and Meta-analysis. Clin Breast Cancer. 2018;18:1–8.CrossRefPubMed
36.
Cai YW, Shao ZM. De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: propensity-matched analysis from a prospectively maintained cohort. Cancer. 2022;128:1748–56.CrossRefPubMed
37.
38.
Boland MR, Ryan EJ, Dunne E, Aherne TM, Bhatt NR. .Lowery A.J. Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer. Br J Surg. 2020;107:33–43.CrossRefPubMed
39.
Davey MG, Ryan EJ, Folan PJ, O’Halloran N, Boland MR, Barry MK, Sweeney KJ, Malone CM, McLaughlin RJ, Kerin MJ et al. The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. BJS Open 2021;5.
Metadata
Title
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
Authors
Hai-long Chen
Feng-bo Huang
Qiang Chen
Yong-chuan Deng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11368-2

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Analysis of neoadjuvant chemotherapy for breast cancer: a 20-year retrospective analysis of patients of a single institution

Research

Functional role and epithelial to mesenchymal transition of the miR-590-3p/MDM2 axis in hepatocellular carcinoma

Research article

Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients

Study Protocol

Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial)

Research

Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival

Research

LMP2 and TAP2 impair tumor growth and metastasis by inhibiting Wnt/β-catenin signaling pathway and EMT in cervical cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits